应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01093 石药集团
已收盘 07-22 16:08:56
6.080
+0.060
+1.00%
最高
6.110
最低
5.970
成交量
2,352万
今开
6.090
昨收
6.020
日振幅
2.33%
总市值
721.07亿
流通市值
721.07亿
总股本
118.60亿
成交额
1.42亿
换手率
0.20%
流通股本
118.60亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
石药集团7月18日获南向资金加仓549.00万股
自选股智能写手 · 07-19
石药集团7月18日获南向资金加仓549.00万股
石药集团07月17日主力资金流入3125万元 连续3日加仓
自选股智能写手 · 07-17
石药集团07月17日主力资金流入3125万元 连续3日加仓
石药集团(01093):呼吸道合胞病毒mRNA疫苗(SYS6016) 获临床试验批准
智通财经 · 07-11
石药集团(01093):呼吸道合胞病毒mRNA疫苗(SYS6016) 获临床试验批准
石药(01093.HK)预防呼吸道合胞病毒疫苗获国家药监局批准开展临床试验
阿斯达克财经 · 07-11
石药(01093.HK)预防呼吸道合胞病毒疫苗获国家药监局批准开展临床试验
石药集团(01093)7月11日注销3635万股已回购股份
智通财经 · 07-11
石药集团(01093)7月11日注销3635万股已回购股份
石药集团7月10日获南向资金加仓940.40万股
自选股智能写手 · 07-11
石药集团7月10日获南向资金加仓940.40万股
石药集团07月10日收跌1.15% 主力资金逆市抢筹
自选股智能写手 · 07-10
石药集团07月10日收跌1.15% 主力资金逆市抢筹
《大行》美银证券降石药(01093.HK)目标价至5.9元 评“跑输大市”
阿斯达克财经 · 07-10
《大行》美银证券降石药(01093.HK)目标价至5.9元 评“跑输大市”
石药集团7月8日获南向资金加仓517.68万股
自选股智能写手 · 07-09
石药集团7月8日获南向资金加仓517.68万股
【券商聚焦】交银国际重申石药集团(01093)买入评级 指其2季度整体运营稳健
金吾财讯 · 07-09
【券商聚焦】交银国际重申石药集团(01093)买入评级 指其2季度整体运营稳健
肾性贫血20亿重磅品种市场要变天?石药抢得首仿,正大天晴、科伦、齐鲁等步步紧逼
医药经济报 · 07-08
肾性贫血20亿重磅品种市场要变天?石药抢得首仿,正大天晴、科伦、齐鲁等步步紧逼
石药集团(01093):抗体药物偶联物SYS6023获美国临床试验批准
智通财经 · 07-08
石药集团(01093):抗体药物偶联物SYS6023获美国临床试验批准
石药集团07月08日获主力加仓1818万元 环比增加586.04%
自选股智能写手 · 07-08
石药集团07月08日获主力加仓1818万元 环比增加586.04%
石药集团7月5日获南向资金加仓712.20万股
自选股智能写手 · 07-08
石药集团7月5日获南向资金加仓712.20万股
石药集团(01093):罗沙司他胶囊获药品注册批件
智通财经 · 07-05
石药集团(01093):罗沙司他胶囊获药品注册批件
石药集团07月04日主力资金流入463万元 连续5日加仓
自选股智能写手 · 07-04
石药集团07月04日主力资金流入463万元 连续5日加仓
港股概念追踪 |多重因素的影响 维生素价格或将进入新一轮涨价周期(附概念股)
智通财经 · 07-04
港股概念追踪 |多重因素的影响 维生素价格或将进入新一轮涨价周期(附概念股)
石药集团7月3日获南向资金加仓491.40万股
自选股智能写手 · 07-04
石药集团7月3日获南向资金加仓491.40万股
屡屡尝到并购甜头的新诺威,这一次却不灵了?
投资时报 · 07-03
屡屡尝到并购甜头的新诺威,这一次却不灵了?
石药(01093.HK):治疗宫颈癌注射液获附条件批准上市
阿斯达克财经 · 07-02
石药(01093.HK):治疗宫颈癌注射液获附条件批准上市
加载更多
公司概况
公司名称:
石药集团
所属市场:
SEHK
上市日期:
--
主营业务:
石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门:成药部门、抗生素(中间体及原料药)部门、维生素C(原料药)部门及咖啡因及其他(原料药)部门,分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。
发行价格:
--
{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":6.08,"timestamp":1721635736027,"preClose":6.02,"halted":0,"volume":23519362,"delay":0,"floatShares":11859741732,"shares":11859741732,"eps":0.5298089,"marketStatus":"已收盘","marketStatusCode":5,"change":0.06,"latestTime":"07-22 16:08:56","open":6.09,"high":6.11,"low":5.97,"amount":142410339,"amplitude":0.023256,"askPrice":6.09,"askSize":26000,"bidPrice":6.08,"bidSize":316000,"shortable":3,"etf":0,"ttmEps":0.5471514728277843,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"listingDate":772128000000,"adjPreClose":6.02,"dividendRate":0.044812,"openAndCloseTimeList":[[1721611800000,1721620800000],[1721624400000,1721635200000]],"volumeRatio":0.759932,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":true,"expireDate":1724860800000,"strike":"7.00","timestamp":1721616131154,"price":0.05000000074505806,"volume":500,"amount":50000,"type":"*"},{"symbol":"CSP.HK","call":true,"expireDate":1722268800000,"strike":"6.50","timestamp":1721616478857,"price":0.019999999552965164,"volume":465,"amount":18600,"type":"*"}]},"impliedVol":0.3432,"impliedVolPercentile":0.2146,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK"},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2452935944","title":"石药集团7月18日获南向资金加仓549.00万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452935944","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452935944?lang=zh_cn&edition=full","pubTime":"2024-07-19 09:31","pubTimestamp":1721352693,"startTime":"0","endTime":"0","summary":"7月18日, 南向资金增持石药集团549.00万股。截止当日收盘,港股通共持有石药集团146219.07万股,占流通股12.32%。石药集团近5个交易日下跌0.49%,港股通累计增持1848.43万股;近20个交易日下跌9.51%,港股通累计增持3544.28万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190942079f68722f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190942079f68722f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1152091168.USD","LU0880133367.SGD","SG9999004220.SGD","LU0067412154.USD","IE00B031HY20.USD","IE0008369823.USD","LU0501845795.SGD","LU1807302812.USD","LU1993786604.SGD","IE00B543WZ88.USD","BK1521","LU0326950275.SGD","LU0072913022.USD","LU1960683339.HKD","LU1226287529.USD","BK1191","LU0140636845.USD","LU1008478684.HKD","01093","BK1515","LU1152091754.HKD","IE0008368742.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2452417182","title":"石药集团07月17日主力资金流入3125万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2452417182","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452417182?lang=zh_cn&edition=full","pubTime":"2024-07-17 16:16","pubTimestamp":1721204180,"startTime":"0","endTime":"0","summary":"07月17日, 石药集团股价涨0.67%,报收6.03元,成交金额2.53亿元,换手率0.35%,振幅1.84%,量比1.13。石药集团今日主力资金净流入3125万元,连续3日净流入,上一交易日主力净流入3092万元,今日环比增加1.07%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为31.58%,平均涨幅为2.11%。该股近5个交易日下跌0.17%,主力资金累计净流入8563万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入2.12亿元,其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071716164595cd6c4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071716164595cd6c4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1960683339.HKD","LU0140636845.USD","IE00B5MMRT66.SGD","LU1807302812.USD","LU1993786604.SGD","LU0072913022.USD","LU0067412154.USD","IE0008368742.USD","LU1152091754.HKD","01093","LU1226287529.USD","BK1521","IE0008369823.USD","BK1191","IE00B543WZ88.USD","SG9999004220.SGD","LU0326950275.SGD","LU1152091168.USD","BK1515","LU1008478684.HKD","IE00B031HY20.USD","LU0501845795.SGD","LU0880133367.SGD"],"gpt_icon":0},{"id":"2450339836","title":"石药集团(01093):呼吸道合胞病毒mRNA疫苗(SYS6016) 获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2450339836","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450339836?lang=zh_cn&edition=full","pubTime":"2024-07-11 17:23","pubTimestamp":1720689805,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团 发布公告,集团开发的呼吸道合胞病毒mRNA疫苗(该产品)已获得中国国家药品监督管理局批准,可以在中国开展临床试验。该产品由编码呼吸道合胞病毒全长融合糖蛋白(F蛋白)融合前构象的mRNA分子包裹于脂质纳米颗粒所构成,适用于预防由RSV感染引起的下呼吸道疾病。目前国内尚无针对RSV感染的疫苗上市,该产品的研发进展在国内属于第一梯队。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226287529.USD","SG9999004220.SGD","LU1008478684.HKD","LU1152091168.USD","LU1152091754.HKD","LU1993786604.SGD","159646","LU1960683339.HKD","IE00B5MMRT66.SGD","LU0140636845.USD","LU1807302812.USD","BK1515","IE0008368742.USD","LU0072913022.USD","LU0880133367.SGD","LU0326950275.SGD","BK1191","IE00B031HY20.USD","IE00B543WZ88.USD","IE0008369823.USD","03347","BK1583","BK1141","LU0501845795.SGD","BK1521","LU0067412154.USD","BK1576","01093"],"gpt_icon":0},{"id":"2450833922","title":"石药(01093.HK)预防呼吸道合胞病毒疫苗获国家药监局批准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2450833922","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450833922?lang=zh_cn&edition=full","pubTime":"2024-07-11 17:22","pubTimestamp":1720689720,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK) 公布,旗下呼吸道合胞病毒(RSV)mRNA疫苗(SYS6016)已获得中国国家药品监督管理局批准,可以在中国开展临床试验。据悉,相关产品适用于预防由RSV感染引起的下呼吸道疾病。公告指,目前内地尚无针对RSV感染的疫苗上市,该产品的研发进展在国内属于第一梯队。石药集团将全力推进该产品的临床研究工作,力争该产品尽快上市,为社会和股东创造出价值。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-11 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1363032/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","159646","BK1515","LU0880133367.SGD","IE0008368742.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","IE0008369823.USD","LU0140636845.USD","LU0326950275.SGD","BK1141","LU1226287529.USD","LU0067412154.USD","LU0072913022.USD","LU1960683339.HKD","BK1521","IE00B031HY20.USD","LU1008478684.HKD","LU1152091754.HKD","LU1807302812.USD","LU1993786604.SGD","SG9999004220.SGD","BK1576","LU1152091168.USD","01093","03347","BK1191","LU0501845795.SGD"],"gpt_icon":0},{"id":"2450336426","title":"石药集团(01093)7月11日注销3635万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2450336426","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450336426?lang=zh_cn&edition=full","pubTime":"2024-07-11 17:19","pubTimestamp":1720689596,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团(01093)公布,于2024年7月11日注销3635万股已回购股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","BK1515","LU1152091168.USD","IE0008369823.USD","LU1807302812.USD","LU1960683339.HKD","LU1993786604.SGD","LU0140636845.USD","BK1521","LU0072913022.USD","LU1152091754.HKD","BK1191","IE00B5MMRT66.SGD","SG9999004220.SGD","LU1226287529.USD","LU1008478684.HKD","LU0326950275.SGD","01093","IE0008368742.USD","LU0067412154.USD","LU0501845795.SGD","IE00B031HY20.USD","LU0880133367.SGD"],"gpt_icon":0},{"id":"2450874494","title":"石药集团7月10日获南向资金加仓940.40万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450874494","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450874494?lang=zh_cn&edition=full","pubTime":"2024-07-11 09:31","pubTimestamp":1720661493,"startTime":"0","endTime":"0","summary":"7月10日, 南向资金增持石药集团940.40万股,连续4日增持。截止当日收盘,港股通共持有石药集团143731.23万股,占流通股12.07%。石药集团近5个交易日下跌2.90%,港股通累计增持2123.10万股;近20个交易日下跌12.75%,港股通累计减持1107.36万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407110943079f3115e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407110943079f3115e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0326950275.SGD","SG9999004220.SGD","LU1152091168.USD","IE00B543WZ88.USD","IE0008369823.USD","LU0072913022.USD","LU0501845795.SGD","LU0140636845.USD","01093","LU1226287529.USD","BK1515","BK1521","LU1960683339.HKD","IE0008368742.USD","IE00B5MMRT66.SGD","LU0067412154.USD","LU1152091754.HKD","IE00B031HY20.USD","LU1993786604.SGD","LU0880133367.SGD","BK1191","LU1807302812.USD","LU1008478684.HKD"],"gpt_icon":0},{"id":"2450857054","title":"石药集团07月10日收跌1.15% 主力资金逆市抢筹","url":"https://stock-news.laohu8.com/highlight/detail?id=2450857054","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450857054?lang=zh_cn&edition=full","pubTime":"2024-07-10 16:17","pubTimestamp":1720599431,"startTime":"0","endTime":"0","summary":"07月10日, 石药集团股价跌1.15%,报收6.02元,成交金额2.68亿元,换手率0.37%,振幅2.63%,量比1.16。石药集团今日主力资金净流入4231万元,上一交易日主力净流入3332万元,今日环比增加26.98%。该股近5个交易日下跌3.55%,主力资金累计净流入1.01亿元;近20日主力资金累计净流入1.54亿元,其中净流入天数为15日。该股主力净额占比0.06%,港股市场排名48/2649。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710161747959d3f07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710161747959d3f07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0140636845.USD","LU0501845795.SGD","BK1515","LU1152091168.USD","LU1960683339.HKD","LU1152091754.HKD","BK1521","IE00B031HY20.USD","LU0067412154.USD","LU0880133367.SGD","LU1008478684.HKD","LU1226287529.USD","LU0326950275.SGD","IE0008368742.USD","BK1191","LU1807302812.USD","LU1993786604.SGD","SG9999004220.SGD","01093","IE00B543WZ88.USD","IE0008369823.USD","LU0072913022.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2450775838","title":"《大行》美银证券降石药(01093.HK)目标价至5.9元 评“跑输大市”","url":"https://stock-news.laohu8.com/highlight/detail?id=2450775838","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450775838?lang=zh_cn&edition=full","pubTime":"2024-07-10 10:45","pubTimestamp":1720579500,"startTime":"0","endTime":"0","summary":"美银证券发表研究报告指,石药集团(01093.HK) 核心产品Pegfilgrastim销售额按年增长近19%,而其他主要产品销售普遍下跌,当中Doxorubicin及Paclitaxel分别下跌1%及8.8%,考虑到核心药物面临降价压力,销售前景受压,相应将集团2024至2026年收入预测下调0.5%、0.4%及0.4%,目标价下调至5.9元,重申“跑输大市”评级。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-09 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1362582/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["161027","01093"],"gpt_icon":0},{"id":"2450053406","title":"石药集团7月8日获南向资金加仓517.68万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450053406","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450053406?lang=zh_cn&edition=full","pubTime":"2024-07-09 09:31","pubTimestamp":1720488684,"startTime":"0","endTime":"0","summary":"7月8日, 南向资金增持石药集团517.68万股。截止当日收盘,港股通共持有石药集团142498.41万股,占流通股11.97%。石药集团近5个交易日下跌2.09%,港股通累计增持2215.08万股;近20个交易日下跌12.37%,港股通累计减持2136.64万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407090942259593e565&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407090942259593e565&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0067412154.USD","LU0140636845.USD","LU0880133367.SGD","SG9999004220.SGD","01093","LU0072913022.USD","BK1515","LU0326950275.SGD","LU0501845795.SGD","LU1226287529.USD","LU1807302812.USD","LU1993786604.SGD","IE00B543WZ88.USD","IE0008368742.USD","BK1191","BK1521","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2450037717","title":"【券商聚焦】交银国际重申石药集团(01093)买入评级 指其2季度整体运营稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2450037717","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450037717?lang=zh_cn&edition=full","pubTime":"2024-07-09 08:47","pubTimestamp":1720486024,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发研报指,石药集团 2季度整体运营稳健。该行预计,公司2季度整体收入/成药业务收入分别增长10%/15%左右。下半年新品销售、上市、医保谈判快速推进。年底的医保谈判中,重点关注PD-1、明复乐脑梗适应症和恩必普续约情况。2)HER2ADC的末线HER2+BC适应症已提交pre-BLA,预计年底前正式提交。该行继续基于DCF模型对公司估值,维持11.0港元的目标价。公司当前股价对应8.7倍2025年市盈率和0.7倍2025年PEG,投资性价比显著,重申买入评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/YjQxYWY4NjkyMTU2YjM4ZTVhNGFhMzYzNjE2NzgxMDU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/YjQxYWY4NjkyMTU2YjM4ZTVhNGFhMzYzNjE2NzgxMDU=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939997","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"gpt_icon":0},{"id":"2449708456","title":"肾性贫血20亿重磅品种市场要变天?石药抢得首仿,正大天晴、科伦、齐鲁等步步紧逼","url":"https://stock-news.laohu8.com/highlight/detail?id=2449708456","media":"医药经济报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449708456?lang=zh_cn&edition=full","pubTime":"2024-07-08 21:01","pubTimestamp":1720443698,"startTime":"0","endTime":"0","summary":"在短短三天时间内,共有6家企业参与了这场激烈的首仿争夺战。事实上,在石药集团身后,还有超过20家药企的罗沙司他胶囊申请上市,包括科伦药业、康臣药业、齐鲁制药、山东新时代、正大天晴等。随着全球人口老龄化,CKD的患病率预计将继续上升。珐博进发布2023年度财报显示,罗沙司他在中国销售额2.84亿美元,合20亿元人民币,同比增长36%。这意味着,阿斯利康方面放弃了该产品的美国市场权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407082106519f1ecc11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407082106519f1ecc11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0880133367.SGD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU0140636845.USD","LU1807302812.USD","BK1515","LU1226287529.USD","BK1191","SG9999004220.SGD","IE00B543WZ88.USD","IE0008368742.USD","LU0072913022.USD","LU1993786604.SGD","LU0501845795.SGD","BK1521","LU0067412154.USD","01093"],"gpt_icon":0},{"id":"2449212327","title":"石药集团(01093):抗体药物偶联物SYS6023获美国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2449212327","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449212327?lang=zh_cn&edition=full","pubTime":"2024-07-08 17:19","pubTimestamp":1720430352,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团 发布公告,集团附属公司石药集团巨石生物制药有限公司开发的抗体药物偶联物SYS6023(该产品)的试验性新药申请已获美国食品药品监督管理局批准,可以在美国开展临床试验。此前,该产品已经于2024年3月获得中华人民共和国国家药品监督管理局批准,可以在中国开展临床试验。SYS6023是一款单克隆抗体药物偶联物,可与肿瘤表面的特异性受体结合,通过内吞作用进入细胞并释放毒素,达到杀伤肿瘤细胞的作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0140636845.USD","LU0501845795.SGD","BK1515","BK1521","LU0067412154.USD","LU0880133367.SGD","LU1226287529.USD","03347","BK1576","LU0326950275.SGD","IE0008368742.USD","BK1191","LU1807302812.USD","LU1993786604.SGD","BK1141","SG9999004220.SGD","01093","IE00B543WZ88.USD","BK1583","LU0072913022.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2449725889","title":"石药集团07月08日获主力加仓1818万元 环比增加586.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449725889","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449725889?lang=zh_cn&edition=full","pubTime":"2024-07-08 16:16","pubTimestamp":1720426619,"startTime":"0","endTime":"0","summary":"07月08日, 石药集团股价跌2.40%,报收6.09元,成交金额2.34亿元,换手率0.32%,振幅3.69%,量比0.96。石药集团今日主力资金净流入1818万元,连续7日净流入,上一交易日主力净流入265万元,今日环比增加586.04%。该股近5个交易日下跌1.93%,主力资金累计净流入7046万元;近20日主力资金累计净流入2115万元,其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081618079f1d620c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081618079f1d620c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B5MMRT66.SGD","SG9999004220.SGD","BK1521","LU1993786604.SGD","BK1515","LU0140636845.USD","LU1807302812.USD","LU0880133367.SGD","IE0008368742.USD","LU0072913022.USD","LU0501845795.SGD","IE00B543WZ88.USD","LU1226287529.USD","LU0067412154.USD","01093","BK1191","LU0326950275.SGD"],"gpt_icon":0},{"id":"2449897718","title":"石药集团7月5日获南向资金加仓712.20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449897718","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449897718?lang=zh_cn&edition=full","pubTime":"2024-07-08 09:31","pubTimestamp":1720402277,"startTime":"0","endTime":"0","summary":"7月5日, 南向资金增持石药集团712.20万股。截止当日收盘,港股通共持有石药集团141980.73万股,占流通股11.92%。港股通增持金额前五个股分别为建设银行、工商银行、中国移动、华晨中国、中国石油化工股份。石药集团近5个交易日下跌1.42%,港股通累计增持1393.84万股;近20个交易日下跌8.91%,港股通累计减持1388.76万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708094011958d30b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708094011958d30b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B5MMRT66.SGD","SG9999004220.SGD","BK1521","01093","BK1515","LU0880133367.SGD","IE0008368742.USD","LU0140636845.USD","IE00B543WZ88.USD","BK1191","LU0326950275.SGD","LU1226287529.USD","LU0067412154.USD","LU0501845795.SGD","LU1807302812.USD","LU1993786604.SGD","LU0072913022.USD"],"gpt_icon":0},{"id":"2449517342","title":"石药集团(01093):罗沙司他胶囊获药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2449517342","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449517342?lang=zh_cn&edition=full","pubTime":"2024-07-05 17:35","pubTimestamp":1720172155,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团 发布公告,集团开发的罗沙司他胶囊(该产品)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件。该产品为中国首仿获批,并视同通过仿制药质量和疗效一致性评价。在《中国肾性贫血诊治临床实践指南》及《罗沙司他治疗肾性贫血中国专家共识》中,罗沙司他获最高级别(1A级)推荐。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999004220.SGD","LU0326950275.SGD","IE00B5MMRT66.SGD","BK1515","LU0072913022.USD","IE00B543WZ88.USD","LU0501845795.SGD","LU0880133367.SGD","LU0140636845.USD","LU1807302812.USD","IE0008368742.USD","LU0067412154.USD","01093","BK1191","LU1993786604.SGD","BK1521","LU1226287529.USD"],"gpt_icon":0},{"id":"2448939411","title":"石药集团07月04日主力资金流入463万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2448939411","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448939411?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:15","pubTimestamp":1720080931,"startTime":"0","endTime":"0","summary":"07月04日, 石药集团股价跌0.81%,报收6.15元,成交金额2.04亿元,换手率0.28%,振幅2.58%,量比0.70。石药集团今日主力资金净流入463万元,连续5日净流入,上一交易日主力净流入3322万元,今日环比减少86.06%。近一年数据显示,该股主力连续5日净流入后,次日上涨概率为20.00%,平均涨幅为1.19%。该股近5个交易日下跌5.50%,主力资金累计净流入6899万元;近20日主力资金累计净流入1095万元,其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041615589f01dcca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041615589f01dcca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1807302812.USD","LU1993786604.SGD","LU1226287529.USD","IE0008368742.USD","BK1515","BK1521","LU0880133367.SGD","01093","LU0326950275.SGD","IE00B5MMRT66.SGD","LU0501845795.SGD","BK1191","IE00B543WZ88.USD","LU0140636845.USD","SG9999004220.SGD","LU0067412154.USD","LU0072913022.USD"],"gpt_icon":0},{"id":"2448940204","title":"港股概念追踪 |多重因素的影响 维生素价格或将进入新一轮涨价周期(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2448940204","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448940204?lang=zh_cn&edition=full","pubTime":"2024-07-04 13:44","pubTimestamp":1720071852,"startTime":"0","endTime":"0","summary":"近日,维生素市场可谓“涨声连连”。近期在原材料成本增加、供给收缩、海外市场补库需求增加以及下游饲料行业刚性需求等多重因素的影响,判断维生素或有望进入新一轮的涨价周期,建议重点关注K3、VD3、VE等品类维生素。一季度原料产品业务收入本期减少8.0%至人民币9.35亿元。由于需求回落,维生素C产品的销售收入减少11.8%至人民币4.86亿元。抗生素产品的销售收入保持平稳,略为减少3.6%至人民币4.49亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07226","BK1191","LU0880133367.SGD","LU1993786604.SGD","01093","BK1515","IE0008368742.USD","00719","SG9999004220.SGD","HSCEI","IE00B543WZ88.USD","LU0072913022.USD","LU0326950275.SGD","YANG","HSTECH","IE00B5MMRT66.SGD","LU0140636845.USD","LU1807302812.USD","LU1226287529.USD","LU0501845795.SGD","LU0067412154.USD","BK1521"],"gpt_icon":0},{"id":"2448229469","title":"石药集团7月3日获南向资金加仓491.40万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448229469","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448229469?lang=zh_cn&edition=full","pubTime":"2024-07-04 09:31","pubTimestamp":1720056690,"startTime":"0","endTime":"0","summary":"7月3日, 南向资金增持石药集团491.40万股。截止当日收盘,港股通共持有石药集团141608.13万股,占流通股11.89%。港股通增持金额前五个股分别为中国移动、工商银行、建设银行、招商银行、中国石油股份。石药集团近5个交易日下跌2.36%,港股通累计增持502.29万股;近20个交易日下跌7.60%,港股通累计减持1024.84万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040941039571c6dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040941039571c6dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0140636845.USD","LU1993786604.SGD","SG9999004220.SGD","LU0067412154.USD","BK1191","BK1515","01093","IE0008368742.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU0501845795.SGD","LU1226287529.USD","LU1807302812.USD","LU0072913022.USD","LU0880133367.SGD","BK1521"],"gpt_icon":0},{"id":"2448266811","title":"屡屡尝到并购甜头的新诺威,这一次却不灵了?","url":"https://stock-news.laohu8.com/highlight/detail?id=2448266811","media":"投资时报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448266811?lang=zh_cn&edition=full","pubTime":"2024-07-03 13:43","pubTimestamp":1719985401,"startTime":"0","endTime":"0","summary":"进入2024年后,颇具并购经验的新诺威又决定将石药百克收入囊中,但这次并购并未再度掀起波澜。新诺威近日发布公告称,此次交易所涉及的尽职调查、审计、评估等各项工作仍在持续推进中。2023年9月12日,新诺威发布公告称,公司计划对石药集团巨石生物实施现金增资18.71亿元。然而,新诺威此次复牌后的走势却出人意料。2023年,新诺威营收实现25.02亿元,同比下滑4.75%,这是其上市以来年度营收首次出现下滑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407031348239ef9af4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407031348239ef9af4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0326950275.SGD","SG9999004220.SGD","IE00B543WZ88.USD","LU0072913022.USD","BK1161","LU0501845795.SGD","LU0140636845.USD","01093","LU1226287529.USD","BK1515","BK1574","BK1521","06978","IE0008368742.USD","IE00B5MMRT66.SGD","LU0067412154.USD","LU1993786604.SGD","LU0880133367.SGD","BK1191","LU1807302812.USD"],"gpt_icon":0},{"id":"2448977862","title":"石药(01093.HK):治疗宫颈癌注射液获附条件批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2448977862","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448977862?lang=zh_cn&edition=full","pubTime":"2024-07-02 10:38","pubTimestamp":1719887880,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK) 公司,集团开发的治疗用生物制品1类新药恩朗苏拜单抗注射液,商品名为恩舒幸已获国家药监局附条件批准上市。该产品本次获批的适应症是用于治疗既往接受含铂化疗治疗失败的PD-L1表达阳性的复发或转移性宫颈癌患者。本次获批主要是基于一项关键II期临床试验。结果显示该产品治疗晚期宫颈癌显著提高了客观缓解率(ORR),独立影像评估委员会评估的ORR达29%,包括2例完全缓解和29例部分缓解,中位缓解持续时间为16.6个月。同时,该产品的安全性良好。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-28 12:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1360620/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0067412154.USD","LU0140636845.USD","LU0880133367.SGD","SG9999004220.SGD","01093","LU0072913022.USD","BK1515","LU0326950275.SGD","LU0501845795.SGD","LU1226287529.USD","LU1807302812.USD","LU1993786604.SGD","IE00B543WZ88.USD","IE0008368742.USD","BK1191","BK1521","IE00B5MMRT66.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0259},{"period":"1month","weight":-0.1055},{"period":"3month","weight":0.0433},{"period":"6month","weight":0.0186},{"period":"1year","weight":-0.0194},{"period":"ytd","weight":-0.1708}],"compareEarnings":[{"period":"1week","weight":-0.0479},{"period":"1month","weight":-0.0549},{"period":"3month","weight":0.0736},{"period":"6month","weight":0.1378},{"period":"1year","weight":-0.0798},{"period":"ytd","weight":0.0217}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门:成药部门、抗生素(中间体及原料药)部门、维生素C(原料药)部门及咖啡因及其他(原料药)部门,分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.007621},{"month":2,"riseRate":0.733333,"avgChangeRate":0.097752},{"month":3,"riseRate":0.466667,"avgChangeRate":0.01981},{"month":4,"riseRate":0.6,"avgChangeRate":0.056282},{"month":5,"riseRate":0.6,"avgChangeRate":0.038173},{"month":6,"riseRate":0.333333,"avgChangeRate":0.004831},{"month":7,"riseRate":0.354839,"avgChangeRate":0.001158},{"month":8,"riseRate":0.433333,"avgChangeRate":0.015994},{"month":9,"riseRate":0.5,"avgChangeRate":-0.005631},{"month":10,"riseRate":0.6,"avgChangeRate":0.0171},{"month":11,"riseRate":0.466667,"avgChangeRate":0.009686},{"month":12,"riseRate":0.5,"avgChangeRate":-0.014286}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}